ALX Oncology (NASDAQ:ALXO) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of ALX Oncology (NASDAQ:ALXO) in a report published on Friday morning,Benzinga reports. Cantor Fitzgerald also issued estimates for ALX Oncology’s FY2025 earnings at ($2.21) EPS.

Other equities research analysts have also issued research reports about the stock. HC Wainwright cut their price target on shares of ALX Oncology from $25.00 to $5.00 and set a “buy” rating for the company in a report on Friday. Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and lowered their target price for the stock from $12.00 to $2.00 in a research note on Thursday, December 19th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $3.50.

ALX Oncology Stock Down 7.1 %

ALXO stock opened at $1.52 on Friday. The firm has a 50 day moving average of $1.61 and a 200 day moving average of $2.42. The stock has a market capitalization of $79.90 million, a PE ratio of -0.51 and a beta of 0.98. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology has a 52 week low of $1.19 and a 52 week high of $17.83.

Insiders Place Their Bets

In other news, Director Rekha Hemrajani purchased 30,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were purchased at an average price of $1.55 per share, with a total value of $46,500.00. Following the transaction, the director now owns 33,000 shares in the company, valued at $51,150. The trade was a 1,000.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 14,443 shares of company stock valued at $23,309 in the last 90 days. 33.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Rhumbline Advisers boosted its position in shares of ALX Oncology by 10.8% during the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock valued at $333,000 after acquiring an additional 5,360 shares during the last quarter. AQR Capital Management LLC lifted its position in ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after buying an additional 6,080 shares during the last quarter. SG Americas Securities LLC lifted its position in ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after buying an additional 6,888 shares during the last quarter. Hsbc Holdings PLC acquired a new position in ALX Oncology in the second quarter valued at about $63,000. Finally, Wellington Management Group LLP lifted its position in ALX Oncology by 15.2% in the third quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock valued at $305,000 after buying an additional 22,114 shares during the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.